BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 7784092)

  • 21. A novel Czech kindred with familial medullary thyroid carcinoma and Hirschsprung's disease.
    Dvoráková S; Dvoráková K; Malíková M; Skába R; Vlcek P; Bendlová B
    J Pediatr Surg; 2005 Jun; 40(6):e1-6. PubMed ID: 15991157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The RET proto-oncogene and cancer.
    Donis-Keller H
    J Intern Med; 1995 Oct; 238(4):319-25. PubMed ID: 7595167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (Sipple's syndrome).
    Oishi S; Sato T; Takiguchi-Shirahama S; Nakamura Y
    Endocr J; 1995 Aug; 42(4):527-36. PubMed ID: 8556060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transcriptome analysis in mouse tumors induced by Ret-MEN2/FMTC mutations reveals subtype-specific role in survival and interference with immune surveillance.
    Engelmann D; Koczan D; Ricken P; Rimpler U; Pahnke J; Li Z; Pützer BM
    Endocr Relat Cancer; 2009 Mar; 16(1):211-24. PubMed ID: 18984779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RET mutation screening in MEN2 patients and discovery of a novel mutation in a sporadic medullary thyroid carcinoma.
    Jhiang SM; Fithian L; Weghorst CM; Clark OH; Falko JM; O'Dorisio TM; Mazzaferri EL
    Thyroid; 1996 Apr; 6(2):115-21. PubMed ID: 8733882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A.
    Berndt I; Reuter M; Saller B; Frank-Raue K; Groth P; Grussendorf M; Raue F; Ritter MM; Höppner W
    J Clin Endocrinol Metab; 1998 Mar; 83(3):770-4. PubMed ID: 9506724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High prevalence of exon 8 G533C mutation in apparently sporadic medullary thyroid carcinoma in Greece.
    Sarika HL; Papathoma A; Garofalaki M; Vasileiou V; Vlassopoulou B; Anastasiou E; Alevizaki M
    Clin Endocrinol (Oxf); 2012 Dec; 77(6):857-62. PubMed ID: 22676047
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel point mutation in the intracellular domain of the ret protooncogene in a family with medullary thyroid carcinoma.
    Hofstra RM; Fattoruso O; Quadro L; Wu Y; Libroia A; Verga U; Colantuoni V; Buys CH
    J Clin Endocrinol Metab; 1997 Dec; 82(12):4176-8. PubMed ID: 9398735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Familial associations in medullary thyroid carcinoma with Hirschsprung disease: the role of the RET-C620 "Janus" genetic variation.
    Moore SW; Zaahl M
    J Pediatr Surg; 2010 Feb; 45(2):393-6. PubMed ID: 20152359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel point mutation in exon 10 of the RET proto-oncogene in a family with medullary thyroid carcinoma.
    Oriola J; Páramo C; Halperin I; García-Mayor RV; Rivera-Fillat F
    Am J Med Genet; 1998 Jul; 78(3):271-3. PubMed ID: 9677065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel 9-base pair duplication in RET exon 8 in familial medullary thyroid carcinoma.
    Pigny P; Bauters C; Wemeau JL; Houcke ML; Crepin M; Caron P; Giraud S; Calender A; Buisine MP; Kerckaert JP; Porchet N
    J Clin Endocrinol Metab; 1999 May; 84(5):1700-4. PubMed ID: 10323403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The relationship of cytomorphology of medullary thyroid carcinomas between family members with the same RET proto-oncogene mutation.
    Chang JS; Chang CF; Yang WS; Chang TC
    Acta Cytol; 2011; 55(6):556-62. PubMed ID: 22156466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RET proto-oncogene mutations in French MEN 2A and FMTC families.
    Schuffenecker I; Billaud M; Calender A; Chambe B; Ginet N; Calmettes C; Modigliani E; Lenoir GM
    Hum Mol Genet; 1994 Nov; 3(11):1939-43. PubMed ID: 7874109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exon 5 of the RET proto-oncogene: a newly detected risk exon for familial medullary thyroid carcinoma, a novel germ-line mutation Gly321Arg.
    Dvorakova S; Vaclavikova E; Duskova J; Vlcek P; Ryska A; Bendlova B
    J Endocrinol Invest; 2005 Nov; 28(10):905-9. PubMed ID: 16419493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC.
    Eng C; Smith DP; Mulligan LM; Healey CS; Zvelebil MJ; Stonehouse TJ; Ponder MA; Jackson CE; Waterfield MD; Ponder BA
    Oncogene; 1995 Feb; 10(3):509-13. PubMed ID: 7845675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Description of the first two seemingly unrelated Greek Cypriot families with a common C618R RET proto-oncogene mutation.
    Neocleous V; Passalaris T; Spanou E; Kitsios P; Skordis N; Deltas CC
    Genet Test; 2004; 8(2):163-8. PubMed ID: 15345114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.
    Donis-Keller H; Dou S; Chi D; Carlson KM; Toshima K; Lairmore TC; Howe JR; Moley JF; Goodfellow P; Wells SA
    Hum Mol Genet; 1993 Jul; 2(7):851-6. PubMed ID: 8103403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of RET mutations in multiple endocrine neoplasia type 2a and familial medullary thyroid carcinoma by denaturing gradient gel electrophoresis.
    Peacock ML; Borst MJ; Sweet JD; Decker RA
    Hum Mutat; 1996; 7(2):100-4. PubMed ID: 8829625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic aspects of familial thyroid cancer.
    Morrison PJ; Atkinson AB
    Oncologist; 2009 Jun; 14(6):571-7. PubMed ID: 19465682
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutations in the cysteine-rich region of the RET proto-oncogene in patients diagnosed as having sporadic medullary thyroid carcinoma.
    Kimura T; Yoshimoto K; Yokogoshi Y; Saito S
    Endocr J; 1995 Aug; 42(4):517-25. PubMed ID: 8556059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.